Persistence of activated and adaptive-like NK cells in HIV+ individuals despite 2 Years of suppressive combination antiretroviral therapy

Anna C. Hearps, Paul A. Agius, Jingling Zhou, Samantha Brunt, Mkunde Chachage, Thomas A Angelovich, Paul U. Cameron, Michelle Giles, Patricia Price, Julian Elliott, Anthony Jaworowski

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Innate immune dysfunction persists in HIV+ individuals despite effective combination antiretroviral therapy (cART). We recently demonstrated that an adaptive-like CD56dim NK cell population lacking the signal transducing protein FcRγ is expanded in HIV+ individuals. Here, we analyzed a cohort of HIV+ men who have sex with men (MSM, n = 20) at baseline and following 6, 12, and 24 months of cART and compared them with uninfected MSM (n = 15) to investigate the impact of cART on NK cell dysfunction. Proportions of NK cells expressing markers of early (CD69+) and late (HLA-DR+/CD38+) activation were elevated in cART-naïve HIV+ MSM (p = 0.004 and 0.015, respectively), as were FcRγ- NK cells (p = 0.003). Using latent growth curve modeling, we show that cART did not reduce levels of FcRγ- NK cells (p = 0.115) or activated HLA-DR+/CD38+ NK cells (p = 0.129) but did reduce T cell and monocyte activation (p < 0.001 for all). Proportions of FcRγ- NK cells were not associated with NK cell, T cell, or monocyte activation, suggesting different factors drive CD56dim FcRγ- NK cell expansion and immune activation in HIV+ individuals. While proportions of activated CD69+ NK cells declined significantly on cART (p = 0.003), the rate was significantly slower than the decline of T cell and monocyte activation, indicating a reduced potency of cART against NK cell activation. Our findings indicate that 2 years of suppressive cART have no impact on CD56dim FcRγ- NK cell expansion and that NK cell activation persists after normalization of other immune parameters. This may have implications for the development of malignancies and co-morbidities in HIV+ individuals on cART.

Original languageEnglish
Article number731
Number of pages12
JournalFrontiers in Immunology
Volume8
Issue numberJUN
DOIs
Publication statusPublished - 30 Jun 2017

Keywords

  • Adaptive-like NK cell
  • Combination antiretroviral therapy
  • HIV
  • Immune activation
  • NK cell

Cite this

@article{eda08328f271485bbbec0b2e659579af,
title = "Persistence of activated and adaptive-like NK cells in HIV+ individuals despite 2 Years of suppressive combination antiretroviral therapy",
abstract = "Innate immune dysfunction persists in HIV+ individuals despite effective combination antiretroviral therapy (cART). We recently demonstrated that an adaptive-like CD56dim NK cell population lacking the signal transducing protein FcRγ is expanded in HIV+ individuals. Here, we analyzed a cohort of HIV+ men who have sex with men (MSM, n = 20) at baseline and following 6, 12, and 24 months of cART and compared them with uninfected MSM (n = 15) to investigate the impact of cART on NK cell dysfunction. Proportions of NK cells expressing markers of early (CD69+) and late (HLA-DR+/CD38+) activation were elevated in cART-na{\"i}ve HIV+ MSM (p = 0.004 and 0.015, respectively), as were FcRγ- NK cells (p = 0.003). Using latent growth curve modeling, we show that cART did not reduce levels of FcRγ- NK cells (p = 0.115) or activated HLA-DR+/CD38+ NK cells (p = 0.129) but did reduce T cell and monocyte activation (p < 0.001 for all). Proportions of FcRγ- NK cells were not associated with NK cell, T cell, or monocyte activation, suggesting different factors drive CD56dim FcRγ- NK cell expansion and immune activation in HIV+ individuals. While proportions of activated CD69+ NK cells declined significantly on cART (p = 0.003), the rate was significantly slower than the decline of T cell and monocyte activation, indicating a reduced potency of cART against NK cell activation. Our findings indicate that 2 years of suppressive cART have no impact on CD56dim FcRγ- NK cell expansion and that NK cell activation persists after normalization of other immune parameters. This may have implications for the development of malignancies and co-morbidities in HIV+ individuals on cART.",
keywords = "Adaptive-like NK cell, Combination antiretroviral therapy, HIV, Immune activation, NK cell",
author = "Hearps, {Anna C.} and Agius, {Paul A.} and Jingling Zhou and Samantha Brunt and Mkunde Chachage and Angelovich, {Thomas A} and Cameron, {Paul U.} and Michelle Giles and Patricia Price and Julian Elliott and Anthony Jaworowski",
year = "2017",
month = "6",
day = "30",
doi = "10.3389/fimmu.2017.00731",
language = "English",
volume = "8",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media",
number = "JUN",

}

Persistence of activated and adaptive-like NK cells in HIV+ individuals despite 2 Years of suppressive combination antiretroviral therapy. / Hearps, Anna C.; Agius, Paul A.; Zhou, Jingling; Brunt, Samantha; Chachage, Mkunde; Angelovich, Thomas A; Cameron, Paul U.; Giles, Michelle; Price, Patricia; Elliott, Julian; Jaworowski, Anthony.

In: Frontiers in Immunology, Vol. 8, No. JUN, 731, 30.06.2017.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Persistence of activated and adaptive-like NK cells in HIV+ individuals despite 2 Years of suppressive combination antiretroviral therapy

AU - Hearps, Anna C.

AU - Agius, Paul A.

AU - Zhou, Jingling

AU - Brunt, Samantha

AU - Chachage, Mkunde

AU - Angelovich, Thomas A

AU - Cameron, Paul U.

AU - Giles, Michelle

AU - Price, Patricia

AU - Elliott, Julian

AU - Jaworowski, Anthony

PY - 2017/6/30

Y1 - 2017/6/30

N2 - Innate immune dysfunction persists in HIV+ individuals despite effective combination antiretroviral therapy (cART). We recently demonstrated that an adaptive-like CD56dim NK cell population lacking the signal transducing protein FcRγ is expanded in HIV+ individuals. Here, we analyzed a cohort of HIV+ men who have sex with men (MSM, n = 20) at baseline and following 6, 12, and 24 months of cART and compared them with uninfected MSM (n = 15) to investigate the impact of cART on NK cell dysfunction. Proportions of NK cells expressing markers of early (CD69+) and late (HLA-DR+/CD38+) activation were elevated in cART-naïve HIV+ MSM (p = 0.004 and 0.015, respectively), as were FcRγ- NK cells (p = 0.003). Using latent growth curve modeling, we show that cART did not reduce levels of FcRγ- NK cells (p = 0.115) or activated HLA-DR+/CD38+ NK cells (p = 0.129) but did reduce T cell and monocyte activation (p < 0.001 for all). Proportions of FcRγ- NK cells were not associated with NK cell, T cell, or monocyte activation, suggesting different factors drive CD56dim FcRγ- NK cell expansion and immune activation in HIV+ individuals. While proportions of activated CD69+ NK cells declined significantly on cART (p = 0.003), the rate was significantly slower than the decline of T cell and monocyte activation, indicating a reduced potency of cART against NK cell activation. Our findings indicate that 2 years of suppressive cART have no impact on CD56dim FcRγ- NK cell expansion and that NK cell activation persists after normalization of other immune parameters. This may have implications for the development of malignancies and co-morbidities in HIV+ individuals on cART.

AB - Innate immune dysfunction persists in HIV+ individuals despite effective combination antiretroviral therapy (cART). We recently demonstrated that an adaptive-like CD56dim NK cell population lacking the signal transducing protein FcRγ is expanded in HIV+ individuals. Here, we analyzed a cohort of HIV+ men who have sex with men (MSM, n = 20) at baseline and following 6, 12, and 24 months of cART and compared them with uninfected MSM (n = 15) to investigate the impact of cART on NK cell dysfunction. Proportions of NK cells expressing markers of early (CD69+) and late (HLA-DR+/CD38+) activation were elevated in cART-naïve HIV+ MSM (p = 0.004 and 0.015, respectively), as were FcRγ- NK cells (p = 0.003). Using latent growth curve modeling, we show that cART did not reduce levels of FcRγ- NK cells (p = 0.115) or activated HLA-DR+/CD38+ NK cells (p = 0.129) but did reduce T cell and monocyte activation (p < 0.001 for all). Proportions of FcRγ- NK cells were not associated with NK cell, T cell, or monocyte activation, suggesting different factors drive CD56dim FcRγ- NK cell expansion and immune activation in HIV+ individuals. While proportions of activated CD69+ NK cells declined significantly on cART (p = 0.003), the rate was significantly slower than the decline of T cell and monocyte activation, indicating a reduced potency of cART against NK cell activation. Our findings indicate that 2 years of suppressive cART have no impact on CD56dim FcRγ- NK cell expansion and that NK cell activation persists after normalization of other immune parameters. This may have implications for the development of malignancies and co-morbidities in HIV+ individuals on cART.

KW - Adaptive-like NK cell

KW - Combination antiretroviral therapy

KW - HIV

KW - Immune activation

KW - NK cell

UR - http://www.scopus.com/inward/record.url?scp=85021696657&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2017.00731

DO - 10.3389/fimmu.2017.00731

M3 - Article

VL - 8

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - JUN

M1 - 731

ER -